Prognostic impact of absolute peripheral blood NK cell count after four cycles of R-CHOP-like regimen treatment in patients with diffuse large B cell lymphoma-Reference-Cited by-同舟云学术

Prognostic impact of absolute peripheral blood NK cell count after four cycles of R-CHOP-like regimen treatment in patients with diffuse large B cell lymphoma

Published:2023-11-08 Issue:8 Volume:23 Page:4665-4672
ISSN:1591-9528
Container-title:Clinical and Experimental Medicine
language:en
Short-container-title:Clin Exp Med

Author:

Huo Zhongjun,Chen Fang,Zhao Jiajia,Liu Ping,Chao Zhi,Liu Kang,Zhou Ji,Zhou Dan,Zhang Lu,Zhen Haifeng,Yang Wenqun,Tan Zhenqing,Zhu Kaibo,Luo Zimian

Abstract

AbstractAs a subtype of lymphocyte, natural killer (NK) cell is the first line of defense that shows a strong function in tumor immunotherapy response and clinical outcomes. The current study aims to investigate the prognostic influence of peripheral blood absolute NK cell count after four cycles of rituximab combined with cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) treatment (NKCC4) in diffuse large B cell lymphoma (DLBCL) patients. A total of 261 DLBCL patients treated with R-CHOP from January 2018 to September 2022 were enrolled. The low NKCC4 was observed in patients who died during the study period compared with survival individuals. A NKCC4 < 135 cells/μl had a remarkable negative influence in overall survival and progression-free survival (PFS) compared to a NKCC4 ≥ 135 cells/μl (p < 0.0001 and p < 0.0004, respectively). In addition, the OS and PFS were synergistically lower in a NKCC4 < 135 cells/μl group among DLBCL patients with GCB type or high IPI. In conclusion, this study indicates NCKK4 as a valuable marker in clinical practice and provides an insight for combination treatment of R-CHOP to improve outcomes of DLBCL patients.

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s10238-023-01249-0.pdf

Reference40 articles.

1. Smith A, Crouch S, Lax S, et al. Lymphoma incidence, survival and prevalence 2004–2014: sub-type analyses from the UK’s haematological malignancy research network. Br J Cancer. 2015;112(9):1575–84. https://doi.org/10.1038/bjc.2015.94.

2. Teras LR, DeSantis CE, Cerhan JR, et al. 2016 US lymphoid malignancy statistics by world health organization subtypes. CA Cancer J Clin. 2016;66(6):443–59. https://doi.org/10.3322/caac.21357.

3. Susanibar-Adaniya S, Barta SK. Update on diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management. Am J Hematol. 2021;96(5):617–29. https://doi.org/10.1002/ajh.26151.

4. Camus V, Belot A, Oberic L, et al. Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial. Blood Adv. 2022;6(24):6169–79. https://doi.org/10.1182/bloodadvances.2022007609.

5. Vahamurto P, Pollari M, Clausen MR, et al. Low absolute lymphocyte counts in the peripheral blood predict inferior survival and improve the international prognostic index in testicular diffuse large b-cell lymphoma. Cancers (Basel). 2020;12(7):1967. https://doi.org/10.3390/cancers12071967.